Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Trial of Orathecin and Gemcitabine Versus Placebo and Gemcitabine in Patients With Non-Resectable Pancreatic Cancer Who Have Not Already Received Chemotherapy

NCT00113256 is registered in ClinicalTrials.gov with Astex Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00113256
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00113256 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Trial of Orathecin and Gemcitabine Versus Placebo and Gemcitabine in Patients With Non-Resectable Pancreatic Cancer Who Have Not Already Received Chemotherapy
Lead sponsor
Astex Pharmaceuticals, Inc.
Phase
Phase 2/3
Overall status
Terminated
Start date
February 28, 2005
Completion date
Not reported
Enrollment
39 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer